35 results on '"Jonat, W."'
Search Results
2. Quality of Life in Goserelin-Treated Versus Cyclophosphamide + Methotrexate + Fluorouracil–Treated Premenopausal and Perimenopausal Patients With Node-Positive, Early Breast Cancer: The Zoladex Early Breast Cancer Research Association Trialists Group
3. Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study
4. Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials
5. Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor of response to neoadjuvant chemotherapy (NACT) in primary breast cancer.
6. Effect of a combination of tyrosine kinase inhibitor imatinib with doxorubicin shows in breast cancer cell lines.
7. Effect of nilotinib on cell proliferation and migration of ovarian cancer cells alone and in combination with standard chemotherapy.
8. Combination with zoledronic acid (ZA) and sunitinib (SU) to reduce severity of osteolytic lesions in bone metatstases.
9. Evaluation of gene expression signatures induced by stromal factors as a predictor of survival in breast cancer.
10. Randomised trial comparing gemcitabine plus vinorelbine (Gem/Vin), gemcitabine plus cisplatin (Gem/Cis), and gemcitabine plus capecitabine (Gem/Cap) in pretreated metastatic breast cancer (MBC)
11. Effects of tamoxifen and imatinib on the radiosensitivity of breast carcinoma cells
12. Neutrophil gelatinase-associated lipocalin (NGAL) is a prognostic marker in human primary breast cancer
13. SU11248 (Sunitinib) does inhibit tumor growth and angiogenesis in an ovarian cancer murine xenograft model
14. Correlation of COX2 expression with tumor-induced osteoclastic lesions in breast cancer bone metastasis
15. Effects of PKC beta inhibitor enzastaurin on chemoresistant ovarian cancer cell lines
16. One Step Nucleic Acid Amplification (OSNA) for intra-operative detection of lymph node metastases in breast cancer patients
17. Increased risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers after breast-conserving therapy compared to mastectomy
18. Survival benefit of switching to anastrozole after 2 years’ treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study
19. Clinical experience using fulvestrant in hormone responsive metastatic breast cancer
20. Imatinib mesylate inhibits the growth of breast cancer cells mediated by PDGF-receptor-β and Akt inactivation
21. Expression of metastasis suppressor gene maspin in breast cancer brain metastases
22. Effects of PKC beta inhibitor enzastaurin on parental and chemoresistant ovarian cancer cell lines
23. Effects of imatinib on breast cancer cell biology in vitro
24. Identification of potential molecular targets for Imatinib mesylate induced growth inhibition in breast cancer cell lines
25. Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial
26. Imatinib mesylate inhibits C-kit and PDGF mediated cell growth in vitro in ovarian cancer
27. Goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with breast cancer. GABG trial IV-B-93
28. Protein profiling utilizing SELDI technology may detect ductal carcinoma in situ (DCIS) with high reliability in patient's serum
29. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
30. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
31. First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin...
32. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
33. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
34. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
35. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.